Rocket names Mirati vet Ondrey CFO 

Gene therapy company Rocket Pharmaceuticals Inc. (NASDAQ:RCKT) made several changes to its management team, including the hiring of Aaron Ondrey as CFO. The company also named existing employees Kinnari Patel as president, head of R&D while remaining COO; Jonathan Schwartz as chief medical and gene therapy officer; Mark White as general manager, commercial affairs; and Martin Wilson as general counsel and chief corporate officer.

The changes come ahead of the June 30 PDUFA date for lead program Kresladi marnetegragene autotemcel to treat severe leukocyte adhesion deficiency-I, which, if approved, would mark Rocket’s transition to a commercial company. Ondrey was most recently CFO at Mirati Therapeutics Inc...